Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X0PW
|
|||
| Former ID |
DIB010802
|
|||
| Drug Name |
Revamilast
|
|||
| Synonyms |
GRC-4039; PDE 4 inhibitor (inflammation), Glenmark; Phosphodiesterase 4 inhibitor (inflammation), Glenmark; Revamilast (inflammation), Glenmark
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Company |
Glenmark Pharmaceuticals Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H9Cl2F2N3O4
|
|||
| Canonical SMILES |
C1=CC(=C2C(=C1C(=O)N=C3C(=CN(C=C3Cl)O)Cl)C4=C(O2)C=CN=C4)OC(F)F
|
|||
| InChI |
1S/C18H9Cl2F2N3O4/c19-10-6-25(27)7-11(20)15(10)24-17(26)8-1-2-13(29-18(21)22)16-14(8)9-5-23-4-3-12(9)28-16/h1-7,18,27H
|
|||
| InChIKey |
CFRXVFRHMZLQBS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 893555-90-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| TSH signaling pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01436890) A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma. U.S. National Institutes of Health. | |||
| REF 2 | WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.